Abiomed Inc (NQ: ABMD )
269.44 USD +1.24 (+0.46%) Streaming Delayed Price Updated: 11:19 AM EST, Nov 23, 2020 Add to My Watchlist
Press releases about Abiomed Inc
First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons
November 05, 2020
Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella...
Axogen, Inc. Reports Third Quarter 2020 Financial Results
October 29, 2020
Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin
October 29, 2020
Abiomed announces Q2 FY 2021 revenue of $210 million, up 27% over Q1 FY 2021 and up 2% over Q2 FY 2020 with 29.2% operating margin.
Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9...
FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology
October 26, 2020
The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.
Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP
October 16, 2020
Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is...
Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women
October 16, 2020
Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect,...
Abiomed to Host a Virtual Meeting to Discuss New Clinical Data Presented at TCT Connect
October 15, 2020
Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes
October 15, 2020
Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when Impella is used to...
Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction
October 14, 2020
The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella-supported high-risk PCI, is associated with significant...
Abiomed will release financial results for the second quarter of fiscal 2021 on Thursday, October 29, 2020 at 8:00 a.m. ET.
TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients
October 08, 2020
The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival...
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
September 30, 2020
Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference
September 14, 2020
Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference
September 08, 2020
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients
August 04, 2020
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19...
Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump
July 30, 2020
A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock...
Abiomed announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021.
FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient Outcomes
July 16, 2020
The United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomed's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external...
Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist
July 01, 2020
The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart...
Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes
June 16, 2020
Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve...
Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief medical officer.
FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump
June 05, 2020
Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a...
Abiomed to Hold Fireside Chat at the William Blair 40th Annual Growth Stock Conference
June 03, 2020
Abiomed will hold a fireside chat at the William Blair 40th Annual Growth Stock Conference (virtual).
FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure
June 01, 2020
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or...